McKinsey helped J&J sell its signature opioid, a narcotic patch called Duragesic. In PowerPoint slides, McKinsey recommended that J&J target “high abuse-risk patients (eg males under 40)” and move physicians who were “stuck” in prescribing less potent opioids into prescribing stronger formulations. Another slide asked, “Are we properly targeting and influencing prescription behavior in pain clinics?”
